References

  1. UNAIDS/World Health Organization, AIDS epidemic update. Joint United Nations Programme on HIV/AIDS-World Health Organization. 200Geneva, Switzerland. UNAIDS/World Health Organization.

  2. Darr ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med. 1991;324(14): 961-964. PubMed | Google Scholar

  3. Lefrère J, Dahourou H, Dokekias AE, Kouao MD, et al. Estimate of the residual risk of transfusion-transmitted human immunodeficiency virus infection in sub-Saharan Africa: a multinational collaborative study. Transfusion. 2011; 51(3):486-492. PubMed | Google Scholar

  4. Lackritz EM, Hightower A, Zucker JR, Ruebush TK, Onudi CO, et al. Blood transfusion practices and blood-banking services in a Kenyan hospital. AIDS. 1993; 7(7):995-999. PubMed | Google Scholar

  5. Kimani D, Mwangi J, Mwangi M, Bunnell R. Blood donors in Kenya: a comparison of voluntary and family replacement donors based on a population-based survey. Vox Sang. 2011; 100(2):212-218. PubMed | Google Scholar

  6. National Population Commission (NPC). National Census Figures. 2007. Abuja, Nigeria. National Population Commission (NPC).

  7. Malone JD, Smith ES, Sheffield J, Bigelow D, Hyams K C, Beardsley S G, Lewis R S, Roberts C R. Comparative evaluation of six rapid serological tests for HIV-1 antibody. J Acquir Immune Defic Syndr. 1993; 6(2): 115-119. PubMed | Google Scholar

  8. Laperche S, Maniez-Montreuil M, Couroucé AM. Screening tests combined with p24 antigen and anti-HIV antibodies in early detection of HIV-1. Transfus Clin Biol. 2000; 7 (1):18s-24s. PubMed | Google Scholar

  9. Gürtler L, Mühlbacher A, Michl U, Hofmann H, Paggi GG, et al. Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. J Virol Methods. 1998; 75(1):27-38. PubMed | Google Scholar

  10. Constantine N. HIV Viral Antigen Assays. HIV InSite Knowledge Base Chapter. September 2001.Baltimore, USA. University of Maryland School of Medicine. PubMed | Google Scholar

  11. Alter HJ, Epstein JS, Swanson SG, Van Raden MJ, Ward JW, et al. Prevalence of immunodeficiency virus type 1 p24 antigen in US blood donors: an assessment of the efficacy of testing in donor screening. N Engl J Med. 1990; 323(19):1312-1318. PubMed | Google Scholar

  12. Gendler SA, Pascuccio MS. Routine HIV screening among blood donors in Buenos Aires (Argentina): results from six years' experience and report of a single window-period donation. Enferm Infecc Microbiol Clin. 2007; 25(2):82-90. PubMed | Google Scholar

  13. Alamawi S, Abutaleb A, Qasem L, Masoud S, Memish Z, Al Khairy K, Kheir O, Bernvil S, Hajeer AH. HIV-1 p24 antigen testing in blood banks: results from Saudi Arabia. Br J Biomed Sci. 2003; 60(2):102-104. PubMed | Google Scholar

  14. Bethesda MD, Food and Drug Administration, Center for Biologics Evaluation and Research. Memorandum to all registered blood and plasma establishments, additional recommendations for donor screening with a licensed test for HIV-1 antigen. March 1996. USA. Food and Drug Administration, Center for Biologics Evaluation and Research. Google Scholar

  15. Germain M, Goldman M. Blood Donor Selection and Screening: Strategies to Reduce Recipient Risk. American Journal of Therapeutics. 2002; 9(5): 406-410. PubMed | Google Scholar

  16. Basavaraju SV, Mwangi J, Nyamongo J, Zeh C, Kimani D, et al. Reduced Risk of Transfusion-transmitted HIV in Kenya through Centrally Co-ordinated Blood Centres, Stringent Donor Selection and Effective p24 Antigen-HIV Antibody Screening. Vox Sanguinis. 2010; 99(3): 212-219. PubMed | Google Scholar

  17. Allain JP, Farrugia A, Sarkodie F. HIV safety in sub-Saharan Africa. Vox Sang. 2011; 100(4):434-435. PubMed | Google Scholar

  18. Vermeulen M, Lelie N, Sykes W, Crookes R, Swanevelder J, Gaggia L, Le Roux M, Kuun E, Gulube S, Reddy R. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion. 2009; 49(6):1115-1125. PubMed | Google Scholar

  19. Machuca A, Hewlett I. Residual risk of human immunodeficiency virus infection in blood banks. Impact of screening with nucleic acid tests. Med Clin (Barc). 2003; 121(11):418-425. PubMed | Google Scholar

  20. Busch MP, Stramer SL, Kleinman SH. Evolving applications of nucleic acid amplification assays for prevention of virus transmission by blood components and derivatives, in Garratty G, Applications of molecular biology to blood transfusion medicine. 1997. USA. American Association of Blood Banks. PubMed | Google Scholar

  21. Nanu A. Blood transfusion services: organization is integral to safety. Natl Med J India. 2001; 14(4):237-240. PubMed | Google Scholar

  22. Koistinen J. Safe blood: the WHO sets out its principles. AIDS Anal Afr. 1992; 2(6):4- 6. PubMed | Google Scholar

  23. Ejele OA, Erhabor O, Nwauche CA. Trends in the prevalence of some transfusion-transmissible infections among blood donors in Port Harcourt, Nigeria. Haema. 2005; 8(2): 273-277. PubMed | Google Scholar

  24. Schreiber GB, Busch M, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infection. N Engl J Med. 1996; 334(26): 1685-1690. PubMed | Google Scholar

  25. Van der Bij AK, Coutinho RA, Van der Poel CL. Surveillance of risk profiles among new and repeat blood donors with transfusion-transmissible infections from 1995 through 2003 in the Netherlands. Transfusion. 2006; 46(10):1729-1736. PubMed | Google Scholar

  26. El-Gilany AH, El-Fedawy S. Blood borne infections among student voluntary blood donors in Mansoura University, Egypt. East Mediterr Health J. 2006; 12(6):742-748. PubMed | Google Scholar

  27. Kalibatas V. Payment for whole blood donations in Lithuania: the risk for infectious disease markers. Vox Sang. 2008; 94(3):209-215. PubMed | Google Scholar

  28. Owusu-Ofori S, Temple J, Sarkodie F, Anokwa M, Candotti D, Allain JP. Pre-donation Screening of Blood Donors with Rapid Tests: Implementation and Efficacy of a Novel Approach to Blood Safety in Resource-Poor Settings. Transfusion. 2005; 45(2): 133-140. PubMed | Google Scholar

  29. Lee HH, Allain JP. Improving Blood Safety in Resource-Poor Settings. Vox Sanguinis. 2004; 87 (2): 176-179. PubMed | Google Scholar

  30. Tayou TC, Tapko JJ, Mbanya D, Lefrere JJ. Blood Safety in Sub-Saharan Africa: a Multi-Factorial Problem. Transfusion. 2008;48 (6):1256-1261. PubMed | Google Scholar

  31. Cable R, Lelie N, Bird A. Reduction of the risk of transfusion-transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: a 5-year review. Vox Sang. 2013; 104(2):93-99. PubMed | Google Scholar

  32. Vermeulen M, Lelie N, Sykes W, Crookes R, Swanevelder J, Gaggia L, et al. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion. 2009; 49(6):1115-1125. PubMed | Google Scholar

  33. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, Weinstein MC. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang. 2004; 86(1):28-40. PubMed | Google Scholar

  34. Akani CI, Erhabor O, Babatunde S. Pre-marital HIV testing in couples from faith-based organisations: experience in Port Harcourt, Nigeria. Niger J Med. 2005 ;14(1):39-44. PubMed | Google Scholar

  35. Ejele OA, Nwauche CA, Erhabor O. Seroprevalence of HIV among unemployed individuals undergoing pre-employment medical examination in Port Harcourt, Nigeria. Niger J Med. 2005; 14(4):419-421. PubMed | Google Scholar

  36. Sayal SK, Das AL, Nema SK. Study of blood groups in HIV seropositive patients. Indian J Dermatol Venereol Leprol. 1996; 62(5):295-297. PubMed | Google Scholar

  37. Banu A, Ahmed SM, Shastri S. Distribution Of ABO and Rh Blood Groups in HIV Seropositives at an Integrated Counseling and Testing Centre in Karnataka, India. SAARC Journal of Tuberculosis, Lung Diseases & HIV/AIDS. 2001; 8(2):42-45. PubMed | Google Scholar

  38. Nneli RO, Ekpo BO, Ohaeri OC, Egene J. Prevalence of Rh and ABO blood groups in HIVseropositive pregnant women in Enugu, Nigeria. Nigerian Journal of Physiological Sciences. 2004; 19(1-2): 7-9. PubMed | Google Scholar

  39. Abdulazeez AA, Alo EB, Rebecca SN. Carriage rate of Human Immunode?ciency Virus (HIV) infection among different ABO and Rhesus blood groups in Adamawa state, Nigeria. Biomedical Research. 2008; 19 (1): 41-44. PubMed | Google Scholar

  40. Ayatollahi H, Rafatpanah H, Khayyami ME, Sayyadpour D, Ravarian M, et al. Association between ABO and Rhesus blood group systems among confirmed human T lymphotropic virus type 1-infected patients in Northeast Iran. AIDS Res Hum Retroviruses. 2008; 24(9):1155-1158. PubMed | Google Scholar